Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kairos Pharma, LTD. (KAPA)

Kairos Pharma amends equity line with Helena, extends use period to December 31, 2028

Neutral Impact 3 of 5 financing Written later

Kairos Pharma amended its equity line of credit purchase agreement with Helena Global Investment Opportunities I Ltd. three times in 2026, changing the purchase price, the pricing period and the period during which the company can use the facility. The company also furnished materials for a November 3, 2026 conference presentation on interim efficacy data for ENV-105. The filing does not state the number of shares or the proceeds involved, but the amendments change the terms under which shares can be sold to Helena, which matters to shareholders.

Key points

  • February 4, 2026: purchase price set at 97% of the average daily VWAP during the Pricing Period.
  • October 26, 2026: Pricing Period shortened from three Trading Days to one Trading Day.
  • October 29, 2026: option to use the equity line extended one year to December 31, 2028.
  • November 3, 2026: President and Chief Scientific Officer Neil Bhowmick presents interim ENV-105 data; median progression-free survival was 17.7 months with the combination versus 2 months with apalutamide alone (P=0.0008).

The filing

CompanyKairos Pharma, LTD. (KAPA)
Form8-K, current report
Filed with the SECNov 3, 2026, 11:50 AM ET
Accession number0001493152-26-049744

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.